- Home
- ELLO vs CRDF Comparison
ELLO vs CRDF Comparison
Compare ELLO & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELLO
- CRDF
- Stock Information
- Founded
- ELLO 1987
- CRDF 1999
- Country
- ELLO Israel
- CRDF United States
- Employees
- ELLO N/A
- CRDF N/A
- Industry
- ELLO Electric Utilities: Central
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELLO Utilities
- CRDF Health Care
- Exchange
- ELLO Nasdaq
- CRDF Nasdaq
- Market Cap
- ELLO 208.2M
- CRDF 240.2M
- IPO Year
- ELLO 1995
- CRDF N/A
- Fundamental
- Price
- ELLO $16.79
- CRDF $3.52
- Analyst Decision
- ELLO
- CRDF Strong Buy
- Analyst Count
- ELLO 0
- CRDF 3
- Target Price
- ELLO N/A
- CRDF $10.33
- AVG Volume (30 Days)
- ELLO 5.4K
- CRDF 1.2M
- Earning Date
- ELLO 12-30-2024
- CRDF 02-27-2025
- Dividend Yield
- ELLO N/A
- CRDF N/A
- EPS Growth
- ELLO N/A
- CRDF N/A
- EPS
- ELLO N/A
- CRDF N/A
- Revenue
- ELLO $44,850,546.00
- CRDF $688,000.00
- Revenue This Year
- ELLO N/A
- CRDF $25.03
- Revenue Next Year
- ELLO N/A
- CRDF N/A
- P/E Ratio
- ELLO N/A
- CRDF N/A
- Revenue Growth
- ELLO N/A
- CRDF 49.57
- 52 Week Low
- ELLO $11.08
- CRDF $1.44
- 52 Week High
- ELLO $20.81
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- ELLO 57.39
- CRDF 46.40
- Support Level
- ELLO $15.86
- CRDF $3.33
- Resistance Level
- ELLO $20.81
- CRDF $4.89
- Average True Range (ATR)
- ELLO 0.93
- CRDF 0.29
- MACD
- ELLO 0.02
- CRDF -0.13
- Stochastic Oscillator
- ELLO 34.21
- CRDF 14.91
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is focused on the utility sector. It is an Israeli public company, which focuses its business in the energy and infrastructure sectors. The company's operating segment includes Photovoltaic power plants (PV Plants); Dorad Energy Ltd. (Dorad); Groen Gas Goor B.V. and a Pumped storage hydro power plant (Manara). It generates maximum revenue from the Dorad segment. Geographically, it derives a majority of its revenue from Spain.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").